Plain-English translation of NCT06966154 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether three medications—tislelizumab, , and —work better together to treat a rare, aggressive type of lymphoma called extranodal NK/T-cell lymphoma (NKTCL) that has returned or stopped responding to previous treatments. The three drugs are designed to work in different ways to fight the cancer cells and boost your immune system. The trial has two parts: first, doctors will carefully test different doses to find the safest combination, and then they will see how well this treatment works in patients who haven't benefited from other therapies.
Most patients with this aggressive lymphoma either don't respond to standard treatments or experience a relapse, and those who have failed previous immunotherapy have very limited options with poor survival rates. This trial is exploring a new three-drug combination that targets the disease through multiple mechanisms to help patients who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive the three medications through a combination of intravenous infusions every 3 weeks and daily or weekly oral pills taken at home. The trial will involve regular clinic visits for blood tests, scans, and check-ins with your doctor to monitor how well the treatment is working and watch for any side effects. Your treatment plan may be adjusted based on how your body tolerates the medications, and the study team will closely track your health throughout the trial.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China